FDA approved repotrectinib for ROS1-positive lung cancer in November 2023Nov 10Regulatory decisionBristol Myers Squibbrepotrectinib
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
BMS posts JAKARTA Phase 3 results, updates Opdivo label, registers golcadomide renal studyAug 13Weekly roundup, 4 itemsBristol Myers Squibbgolcadomide